3,5-Dimethyl-2,4-Imidazolidinedione → 1-{4-[4-(5-Cyclopropyl-3-methylpyridin-2-yl)piperazine-1-carbonyl]phenyl}-3,5-dimethylimidazolidine-2,4-dione
반응식
Br[C:2]1[CH:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][N:13]([C:16]3[C:21]([CH3:22])=[CH:20][C:19]([CH:23]4[CH2:25][CH2:24]4)=[CH:18][N:17]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:4][CH:3]=1.[CH3:26][N:27]1[C:31](=[O:32])[CH:30]([CH3:33])[NH:29][C:28]1=[O:34]>>[CH:23]1([C:19]2[CH:20]=[C:21]([CH3:22])[C:16]([N:13]3[CH2:14][CH2:15][N:10]([C:8]([C:5]4[CH:6]=[CH:7][C:2]([N:29]5[CH:30]([CH3:33])[C:31](=[O:32])[N:27]([CH3:26])[C:28]5=[O:34])=[CH:3][CH:4]=4)=[O:9])[CH2:11][CH2:12]3)=[N:17][CH:18]=2)[CH2:25][CH2:24]1참가 물질
3
실험 절차
Using (4-bromophenyl) [4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone (160 mg) described in Preparation Example 185 and 3,5-dimethylimidazolidine-2,4-dione (51 mg) described in Preparation Example 217 and by the reaction and treatment in the same manner as in Example 536, the title compound (20 mg) was obtained.